Compare Paychex, Inc. (PAYX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs TG Therapeutics Inc — how do they compare? Paychex, Inc. trades at $114.78 (market cap $43.33B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Paychex, Inc. is far larger — about 5.1× TG Therapeutics Inc's market cap, and Paychex, Inc. pays a 3.91% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PAYX | TGTX | |
|---|---|---|
Market Cap | $43.33B | $8.53B |
Sector | Industrials | Health |
52-Week High | $135.46 | $59.06 |
52-Week Low | $85.57 | $26.94 |
Enterprise Value | $46.81B | $8.74B |
Dividend Yield | 3.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $116.93, down 3.93% over the past day, near the consensus price target of $118.17. The stock shows strong profitability with a 27.03% net income margin and 44.77% ROE, though valuation ratios like a P/E of 24.89 and P/S of 6.73 are elevated. Recent quarters have consistently beaten EPS estimates, and the company is advancing its AI-driven WISE platform to enhance payroll efficiency. Technical indicators are mixed, with a bearish moving average signal but an oversold RSI suggesting potential near-term support.
The outlook for PAYX is cautiously optimistic, supported by steady earnings beats and strategic AI integration, but high valuation and mixed analyst sentiment pose risks. Investment opportunity lies in continued execution on margin expansion and market share gains in HR solutions, while key risks include competitive pressures and economic sensitivity affecting small business clients.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
